Higher baseline pain tolerance indicates preserved mitochondrial function and vagal tone, which together buffer inflammaging and keep epigenetic age lower than chronological age. We propose that individuals scoring in the top quartile of pressure‑pain threshold (PPT) will show significantly younger GrimAge and DunedinPoAm scores after adjusting for age, sex, BMI, and habitual physical activity. Conversely, low PPT will predict accelerated epigenetic aging independent of current pain status.

Mechanistically, pain tolerance depends on central endogenous opioid release and peripheral nociceptor sensitization, both modulated by mitochondrial ATP production in glia and neurons. Healthy mitochondria generate sufficient ATP for potassium buffering and GABAergic inhibition, raising the threshold for pain perception. Mitochondrial dysfunction elevates reactive oxygen species, activates NF‑κB, and increases pro‑inflammatory cytokines that sensitize nociceptors and lower threshold. The vagal anti‑inflammatory reflex, driven by acetylcholine release, also relies on mitochondrial NAD+ availability; reduced NAD+ diminishes vagal tone, lowering tolerance and increasing inflammaging. Thus pain tolerance integrates mitochondrial resilience, autonomic balance, and low‑grade inflammation—key drivers of epigenetic aging.

This hypothesis builds on prior work linking chronic pain to accelerated GrimAge, PhenoAge, and DunedinPoAm [1], and on evidence that elite athletes exhibit higher pain tolerance than non‑athletes [3] and that habitual physical activity predicts greater tolerance over time [4]. It extends the literature by testing whether tolerance, rather than pain pathology, serves as a biomarker of youthful biology, and by proposing mitochondrial NAD+ and vagal activity as mechanistic mediators.

To test this, we will recruit 200 adults aged 30‑70, stratified by sex and BMI. Pain tolerance will be assessed using a handheld algometer to determine PPT at the trapezius muscle (three trials, average taken). Blood samples will be collected for DNA methylation analysis to compute GrimAge and DunedinPoAm [1], plasma NAD+ levels, and a cytokine panel (IL‑6, TNF‑α, CRP). Heart‑rate variability (RMSSD) will index vagal tone. Physical activity will be quantified via the International Physical Activity Questionnaire (IPAQ) [4].

Statistical plan: Linear regression will model epigenetic age as a function of PPT quartile, adjusting for chronological age, sex, BMI, and IPAQ score. Mediation analysis will test whether plasma NAD+ and RMSSD account for the PPT‑epigenetic age relationship. We expect the top PPT quartile to exhibit a GrimAge approximately 2.5 years younger than the bottom quartile, with mitochondrial NAD+ explaining ~40% of this effect.

Falsifiability: If, after controlling for NAD+ levels and vagal tone, PPT no longer predicts younger epigenetic age (p>0.05), the hypothesis is refuted. Likewise, if low PPT fails to associate with accelerated epigenetic aging independent of current pain reports, the causal direction would be questioned.

Potential confounders such as acute analgesic use, neuropathy, or recent injury will be screened and excluded. By linking a simple, non‑invasive sensory test to molecular signatures of aging, this work could offer a low‑cost proxy for biological age that outperforms existing clocks in certain populations.